Flatiron Health Expands NSCLC Dataset with Comprehensive Biomarker Model — Flatiron Health, Inc.

Event summary

Flatiron Health expanded its NSCLC Panoramic dataset with a comprehensive biomarker data model, covering 345,000+ patients.
The dataset now includes specimen-level molecular detail for guideline-recommended biomarkers like EGFR, BRAF, KRAS, and emerging biomarkers like KEAP1, STK11.
The expansion enables research on biomarker-driven treatment patterns, patient outcomes, and evolving testing practices in NSCLC.
Over 70% of leading biopharma companies use Flatiron’s NSCLC Panoramic datasets for research.

The big picture

Flatiron Health's expansion of its NSCLC dataset underscores the growing importance of real-world data in precision medicine. By providing specimen-level biomarker detail at scale, Flatiron is positioning itself as a critical partner for biopharma companies developing targeted therapies. This move aligns with broader industry trends toward personalized cancer treatment and the increasing reliance on real-world evidence for regulatory and commercial decisions.

What we're watching

Data Utilization: How biopharma partners will leverage the expanded dataset for precision therapy development and regulatory submissions.
Research Applications: The pace at which the dataset enables breakthroughs in biomarker prevalence studies and resistance mechanism analysis.
Market Differentiation: Whether Flatiron can sustain its competitive edge with deeper biomarker data amid increasing competition in real-world evidence.